Bristol-Myers Squibb (NYSE:BMY) Shares Sold by OPTIMAS CAPITAL Ltd

OPTIMAS CAPITAL Ltd reduced its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 32.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,400 shares of the biopharmaceutical company's stock after selling 20,500 shares during the period. Bristol-Myers Squibb makes up about 3.2% of OPTIMAS CAPITAL Ltd's holdings, making the stock its 14th largest holding. OPTIMAS CAPITAL Ltd's holdings in Bristol-Myers Squibb were worth $2,398,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Swedbank AB increased its holdings in shares of Bristol-Myers Squibb by 0.9% in the third quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock worth $162,440,000 after buying an additional 28,427 shares during the period. Pettinga Financial Advisors LLC increased its holdings in Bristol-Myers Squibb by 8.7% during the 3rd quarter. Pettinga Financial Advisors LLC now owns 11,108 shares of the biopharmaceutical company's stock valued at $575,000 after purchasing an additional 886 shares during the period. United Bank increased its holdings in Bristol-Myers Squibb by 2.7% during the 3rd quarter. United Bank now owns 17,322 shares of the biopharmaceutical company's stock valued at $896,000 after purchasing an additional 456 shares during the period. Natixis Advisors LLC increased its holdings in Bristol-Myers Squibb by 34.9% during the 3rd quarter. Natixis Advisors LLC now owns 446,364 shares of the biopharmaceutical company's stock valued at $23,095,000 after purchasing an additional 115,361 shares during the period. Finally, Thrivent Financial for Lutherans increased its holdings in Bristol-Myers Squibb by 4.9% during the 3rd quarter. Thrivent Financial for Lutherans now owns 116,801 shares of the biopharmaceutical company's stock valued at $6,044,000 after purchasing an additional 5,407 shares during the period. Institutional investors own 76.41% of the company's stock.

Remove Ads

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat acquired 1,823 shares of the stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, for a total transaction of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.09% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BMY has been the topic of several research reports. Bank of America reaffirmed a "neutral" rating and set a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and lifted their price objective for the company from $63.00 to $70.00 in a research report on Monday, December 16th. Cantor Fitzgerald lifted their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Wells Fargo & Company lifted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, Citigroup lifted their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $57.86.

Bristol-Myers Squibb Price Performance

Shares of BMY traded up $0.64 during midday trading on Friday, hitting $61.06. 25,864,960 shares of the company traded hands, compared to its average volume of 12,180,118. The firm has a 50 day moving average of $58.17 and a 200-day moving average of $55.89. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The stock has a market cap of $123.92 billion, a price-to-earnings ratio of -13.82, a PEG ratio of 2.07 and a beta of 0.43. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. On average, analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.06%. The ex-dividend date is Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.